Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
What chemotherapy regimens would be appropriate for cisplatin-ineligible patients to receive concurrently with definitive radiotherapy for locally advanced (inoperable) thymic carcinoma?
Related Questions
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
For patients with biphasic mesothelioma who complete pleurectomy/decortication, would you consider offering adjuvant combination immune checkpoint inhibitor therapy vs. platinum chemotherapy?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?
Which regimen do you recommend for chemoradiation for a patient with locally advanced, inoperable thymic tumor in the setting of CKD Stage III?
In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?